
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout t... Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.63 | -22.02680067 | 11.94 | 12.5 | 9.31 | 331159 | 11.44582519 | CS |
4 | -2.39 | -20.4273504274 | 11.7 | 12.56 | 8.91 | 202403 | 10.91049604 | CS |
12 | 0.28 | 3.1007751938 | 9.03 | 12.56 | 6.11 | 185901 | 9.53318703 | CS |
26 | -0.32 | -3.32294911734 | 9.63 | 12.56 | 5.83 | 219614 | 8.9916155 | CS |
52 | -0.7104 | -7.08953734382 | 10.0204 | 26.2508 | 5.83 | 175989 | 11.19450437 | CS |
156 | -0.7104 | -7.08953734382 | 10.0204 | 26.2508 | 5.83 | 58585 | 11.19450437 | CS |
260 | -0.7104 | -7.08953734382 | 10.0204 | 26.2508 | 5.83 | 37372 | 11.19450437 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions